HR 3873
KO Cancer Act
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
The KO Cancer Act aims to significantly increase funding for cancer research at the National Cancer Institute (NCI). The bill proposes a substantial increase in NCI’s budget, specifically targeting 25% of the institute’s 2022 funding over a period of nine years. It also directs the Department of Health and Human Services to investigate and report on the causes of cancer drug shortages, with the goal of finding solutions to improve access to these medications.
Key provisions
- Increases NCI funding by 25% over nine years (2026-2030).
- Allocates funds based on 2022 NCI appropriations.
- Directs a study of cancer drug shortages.
- Requires a report to Congress detailing the causes of drug shortages.
- The report must include recommendations for addressing these shortages.
- The study will examine economic, supply chain, and regulatory factors.
- The study will consider the development and approval processes for cancer drugs.
- The study will assess the availability of generic and biosimilar drugs.
Who is affected
- Cancer patients
- Cancer researchers
- National Cancer Institute
- Department of Health and Human Services
- Pharmaceutical industry
Notable changes
- Proposes a substantial increase in cancer research funding.
- Mandates a comprehensive study of cancer drug shortages.
- Focuses on addressing the root causes of drug shortages to improve patient access.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.
119th CONGRESS — 1st Session
H. R. 3873
IN THE HOUSE OF REPRESENTATIVES
A BILL
To increase funding for cancer research by the National Cancer Institute to be more in proportion to the mortality rates of cancer.
This Act may be cited as the Knock Out Cancer Act KO Cancer Act
or the
.
Congress finds the following:
Cancer is one of the leading causes of death in the world and has touched nearly every life, either directly or indirectly.
Cancer is the cause of nearly 1 out of every 4 deaths in the United States, since 2000 totaling over 15 million American lives.
Efforts to increase awareness of cancer symptoms among patients and clinicians would lead to earlier detection and improvements in survival rates.
Scientific understanding and research lead to innovations in effective treatments, controls, and cures for cancer.
The National Cancer Institute has been a leader in finding medical breakthroughs for treatment and therapies for cancer patients.
Through substantial investment in cancer research, potentially even the tripling of necessary funding, the United States will be best able to address the mortality rates of cancer and the impacts on the patient population.
To conduct or support cancer research, there is hereby appropriated, for each of fiscal years 2026 through 2030, to the National Cancer Institute, out of amounts in the Treasury not otherwise appropriated, an amount that is equal to 25 percent of the total amount appropriated to the National Cancer Institute for fiscal year 2022, to remain available until expended. Amounts appropriated pursuant to the preceding sentence shall be in addition to amounts otherwise made available to the National Cancer Institute.
economic reasons;
supply chain failures;
delays and other complications relating to—
the development of cancer drugs; and
the approval of such drugs by the Food and Drug Administration; and
insufficient generic drugs and biosimilar biological products.
Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall complete the study under subsection (a) and submit a report to the appropriate committees of the Congress on the results of such study.
The report under paragraph (1) shall include recommendations for addressing the reasons for cancer drug shortages.